Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZGGS18 in advanced solid tumors
NCT05584800Phase 2Recruiting
- Sponsor
- Zelgen
- Start
- Nov 2022
- Primary completion
- Nov 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of ZGGS18 in solid tumor (advanced stage), sponsored by Zelgen. Started Nov 2022; status: recruiting.
02
Drugs
ZGGS18
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05584800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05584800.